We further demonstrate that inhibiting PI3K with LY294002 reduces the survival of all AML cell lines tested, however LY294002 is not suitable for use as a clinical drug due to its high levels of toxicity in-vivo. The gene discussed is PIK3CD; the disease is acute myeloid leukemia.